- Kazia Therapeutics ( NASDAQ: KZIA ) gained ~31% pre-market Thursday after the oncology-focused biotech announced that its lead candidate, paxalisib demonstrated anti-tumor activity in multiple preclinical models with the metastatic form of skin cancer melanoma.
- The research was a partnership between Kazia ( KZIA ) and the Huntsman Cancer Institute at the University of Utah.
- According to data presented at the International Congress of the Society for Melanoma Research, paxalisib, licensed from the Genentech unit of Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), was found to be active in vitro and in vivo against metastatic melanoma preclinical models, the company said.
- Paxalisib indicated significant activity as a single agent, and in combination with MEK and BRAF inhibitors, two commonly used melanoma therapies.
- The collaboration is ongoing, and further clinical studies for paxalisib are expected ahead of future clinical advancement.
For further details see:
Kazia jumps 31% on pre-clinical data for skin cancer therapy